Apceth, Cologne University to develop combination cellular immunotherapies for cancer
The collaboration is based on combinations of Chimeric Antigen Receptor (CAR) T cells, developed at the laboratory of professor Hinrich Abken against multiple tumor-associated antigens, and apceth-developed engineered
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.